Pre-clinical work has demonstrated that anti-tumor activity of PARP inhibitors is not only impacted by inhibition of enzymatic function (suppression of parylation), but also by sequestration (“trapping”) of PARP complexes at sites of DNA damage – preventing efficient repair and leading to cell death (58, 59). Here, PARP1 is linked to neoplasm.